Physician profile
Jay S Fenster
NPI 1467434126
$11,281.86
in general payments reported to CMS, 2019-2025
35 companies · $3,762 in 2025
The $3,762 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,162 · 2020: $491 · 2021: $914 · 2022: $1,201 · 2023: $1,888 · 2024: $1,864 · 2025: $3,762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,587 · Debt Forgiveness: $1,927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,586.90 |
| Debt Forgiveness | $1,927.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $1,927.05 | 2023-2025 | |
| Abbvie INC. | $1,490.75 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,143.56 | 2019-2024 | Xifaxan, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $956.42 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $814.71 | 2019-2025 | Tremfya, Stelara, Simponi |
| Lilly USA, LLC | $530.49 | 2023-2025 | Omvoh, Zepbound |
| Pfizer INC. | $481.08 | 2023-2025 | |
| Braintree Laboratories, INC. | $438.94 | 2019-2025 | Sutab, Suflave |
| Regeneron Healthcare Solutions, INC. | $400.44 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $335.54 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $309.80 | 2019-2023 | Rebyota |
| Gilead Sciences, INC. | $308.31 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $260.29 | 2023-2025 | Voquezna |
| Ardelyx, INC. | $252.03 | 2022-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $183.87 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $161.88 | 2021-2022 | |
| Genzyme Corporation | $153.64 | 2022-2025 | |
| Qol Medical, LLC | $148.14 | 2019-2025 | Sucraid, Sucraid |
| Intra-Sana Laboratories | $139.76 | 2022-2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Redhill Biopharma INC. | $121.63 | 2020-2022 | |
| Ironwood Pharmaceuticals, INC | $118.14 | 2020-2024 | |
| Allergan, INC. | $78.40 | 2019 | |
| Evoke Pharma, INC. | $77.52 | 2022-2023 | Gimoti |
| Intercept Pharmaceuticals, INC. | $70.93 | 2019-2023 | Ocaliva |
| Celltrion USA INC. | $63.31 | 2025 | Vegzelma |
| Ipsen Biopharmaceuticals, INC | $53.99 | 2025 | Iqirvo |
| Novo Nordisk INC | $46.01 | 2025 | Wegovy |
| Organon LLC | $43.83 | 2023 | Renflexis, Hadlima |
| Capsovision, INC. | $43.35 | 2023-2024 | Capsocam Plus |
| Janssen Pharmaceuticals, INC | $24.66 | 2022 | |
| Exact Sciences Corporation | $23.24 | 2025 | The Cologuard Plus Collection Kit |
| W. L. Gore & Associates, INC. | $22.14 | 2021 | |
| Daiichi Sankyo INC. | $21.79 | 2020 | |
| Concordia Pharmaceuticals INC. | $20.00 | 2019 | |
| Alfasigma USA, INC. | $16.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Fenster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.